醒腦靜注射液對高血壓腦出血患者臨床指標的影響分析

周麗麗　孫梅芬

[摘要] 目的 分析醒腦靜注射液對高血壓腦出血患者胰島素樣生長因子、一氧化氮等臨床指標的影響作用。 方法 選取2015年6月12日～2017年7月30日于本院進行治療的100例高血壓腦出血患者作為研究對象，所有患者均在本院實施開顱或引流手術，將患者隨機分為兩組，每組50例，一組為對照組，治療方式：依達拉奉注射液30 mg與5%葡萄糖注射液500 mL混合，靜脈滴注，2次/d；另一組為觀察組，治療方式：在對照組治療基礎上加用醒腦靜注射液30 mL，靜脈滴注，1次/d，15 d為一個療程，分析兩組患者經治療后的巨噬細胞轉移抑制因子、一氧化氮和胰島素樣生長因子三項臨床指標的變化、并發癥情況和治療的有效率。 結果 觀察組治療的總有效率為88%，對照組治療總有效率為70%；觀察組患者的MIF水平為（45.12±13.11）ng/L，IGF-1水平為（62.03±11.13）nmol/L，NO水平為（53.31±10.42）μmol/L；對照組患者的MIF水平為（59.02±11.42）ng/L，IGF-1水平為（45.42±13.62）nmol/L，NO水平為（33.52±11.15）μmol/L，兩組患者間差異有統計學意義（P<0.05）；觀察組患者術后有1例出現腦積水、1例出現發熱現象；對照組患者有6例出現腦積水，10例出現發熱現象、3例發生顱內感染，兩組患者差異有統計學意義（P<0.05）。 結論 醒腦靜注射液對于高血壓腦出血患者手術后具有良好的治療效果，能夠降低患者的巨噬細胞轉移抑制因子水平，同時提升一氧化氮和胰島素樣生長因子水平，有效抑制了術后并發癥的發生，對于改善患者的病情具有積極作用，可在臨床治療中進行推廣。

[關鍵詞] 高血壓；腦出血；醒腦靜注射液；臨床指標

[中圖分類號] R743.2 [文獻標識碼] B [文章編號] 1673-9701（2017）36-0116-03

[Abstract] Objective To analyze the influencing effect of Xingnaojing injection on the clinical indexes such as insulin-like growth factor and nitric oxide in the patients with hypertensive intracerebral hemorrhage. Methods A total of 100 patients with hypertensive intracerebral hemorrhage who were treated in our hospital from June 12， 2015 to July 30， 2017 were selected as the study subjects. All patients were given craniotomy or drainage surgery in our hospital. The patients were randomly divided into two groups， with 50 cases in each group. One group was the control group， and the treatment method was that 30 mg edaravone injection was mixed with 500 mL 5% glucose injection for intravenous infusion twice a day； the other group was the observation group， and the treatment method was that on the basis of the control group， 30 mL Xingnaojing injection intravenous drip was given once a day. 15 d was a course of treatment. The changes of the three clinical indexes of macrophage metastasis inhibitor， nitric oxide and insulin-like growth factor after treatment， and the complications and the therapeutic efficiency were compared and analyzed between the two groups. Results The total effective rate in the observation group was 88%， and the total effective rate in the control group was 70%； the level of MIF in the observation group was（45.12±13.11）ng/L， the level of IGF-1 was（62.03±11.13）nmol/L， and the level of NO was（53.31±10.42）μmol/L； the level of MIF in the control group was（59.02±11.42）ng/L， the level of IGF-1 was（45.42±13.62）nmol/L， and the level of NO was（33.52±11.15）μmol/L. The differences between the two groups were statistically significant（P<0.05）. In the observation group， one case had hydrocephalus and one case had fever after the surgery. There were 6 cases of hydrocephalus in control group， 10 cases of fever and 3 cases of intracranial infection. There were statistically significant differences between the two groups（P<0.05）. Conclusion Xingnaojing injection has a good therapeutic effect on the patients with hypertensive intracerebral hemorrhage after surgery， which can reduce the level of macrophage metastasis inhibitor. At the same time it can improve the levels of nitric oxide and insulin-like growth factor， effectively inhibit the occurrence of postoperative complications， and has a positive effect in improving the patient's disease conditions， which can be promoted in clinical treatment.

[Key words] Hypertension；Cerebral hemorrhage；Xingnaojing injection；Clinical indexes

腦出血是高血壓疾病常見的一種并發癥，腦出血對患者生命存在嚴重危害，如不能盡快采取有效治療，很可能造成患者死亡，目前臨床上常用開顱或引流手術并聯合藥物進行治療。巨噬細胞轉移抑制因子、一氧化氮和胰島素樣生長因子三者的動態平衡則是衡量患者腦脊液和血清等其它細胞因素是否平衡的重要標準。在以往的治療當中，術后的常用藥物依達拉奉注射液，但該方法治療效果不高，治愈……